Abstract:Background: To assess the effectiveness of Shugan Jieyu capsules on peripheral blood miR-124, miR-132, and brain-derived neurotrophic factor (BDNF) levels in patients with mild to moderate depression following coronary artery intervention [percutaneous coronary intervention (PCI)] for coronary heart disease. Aim: To evaluate the therapeutic efficacy of Shugan Jieyu capsules and their effects on the peripheral blood levels of miR-124, miR-132, and BDNF in patients with mild to moderate depression following PCI for coronary heart disease. Methods: Patients with mild-to-moderate depression of the liver-qi stagnation type after PCI for coronary heart disease at the 305th Hospital of the People's Liberation Army were enrolled from June 2022 to November 2023 and randomly assigned to two groups: Experimental (treated with Shugan Jieyu capsules) and control (treated with escitalopram oxalate tablets). This study compared the antidepressant effects of these treatments using 17-item Hamilton Rating Scale for Depression (HAMD-17) scores, metabolic equivalents, low-density lipoprotein cholesterol, BDNF, high-sensitivity C-reactive protein levels, miR-124 and miR-132 levels, distribution of immune-related lymphocyte subsets, and traditional Chinese medicine syndrome scores before and after 6 weeks of treatment. Results: No significant difference was observed in any index between the two groups before treatment (P > 0.05). After treatment, the total efficacy rates were 93.33% and 90.00% in the experimental and control groups, respectively. Experimental group had significantly lower scores for the main and secondary syndromes compared to the control group (P < 0.05). No significant difference was observed in the metabolic equivalents between the two groups before and after treatment (P > 0.05). The levels of low-density lipoprotein cholesterol, high-sensitivity C-reactive protein, and miR-132 were significantly lower, whereas those of miR-124, BDNF, CD3+T lymphocytes, CD3+CD4+T helper lymphocytes, and CD3+CD4+/CD3+CD8+ cells were significantly higher in the experimental group compared to the control group (P < 0.05). The incidence of adverse reactions during experimental group was significantly lower than that in control group (P < 0.05). Conclusion: Shugan Jieyu capsules have good efficacy in patients with mild-to-moderate depression after PCI, and its mechanism may contribute to the regulation of miR-124, miR-132, BDNF levels, and lymphoid immune cells.

Clinical trial of bajitian oligosaccharide capsules in the treatment of depression

Gut Microbiota in Bipolar Depression and Its Relationship to Brain Function: an Advanced Exploration

The Efficacy and Safety of Sulforaphane As an Adjuvant in the Treatment of Bipolar Depressive Disorder

Efficacy and Safety of Morinda Officinalis Oligose Capsule in the Treatment of Mild or Moderate Depression

Effect of Compound Lactic Acid Bacteria Capsules on the Small Intestinal Bacterial Overgrowth in Patients with Depression and Diabetes: A Blinded Randomized Controlled Clinical Trial

Effects of morinda officinalis oligoseon on plasma levels of BDNF, GDNF, VEGF and IGF-1 in depressed patients

Randomized, Double Blind, Placebo-Controlled Trial of Shuganjieyu Capsule in the Treatment of Mild or Moderate Depression

Randomized,multicenter,double Blind Comparative Trial of Jin-yu-kang Capsule in the Treatment of Mild and Moderate Depression

Efficacy and safety of Jinyukang capsules in the treatment of mild and moderate depression

Shugan Jieyu capsule effects on peripheral blood micro-124, micro-132, and brain-derived neurotrophic factor in patients with mild to moderate depression

Clinical trial of Wuling capsules in the treatment of Parkinson's disease with depression

Citalopram in the Treatment of Depressive Disorders: an Open Label, Multicenter Study in China

Bacillus coagulans MTCC 5856 for the management of major depression with irritable bowel syndrome: a randomised, double-blind, placebo controlled, multi-centre, pilot clinical study

Clinical efficacy and safety of Guipi decoction combined with escitalopram oxalate tablets in patients with depression

A Randomized, Double-Blind, Positive-Controlled, Multicenter Clinical Trial on the Efficacy and Safety of ShuganJieyu Capsule and St. John's Wort for Major Depressive Disorder with Somatic Complaints

Antidepressant evaluation of polysaccharides from a Chinese herbal medicine Banxia-houpu decoction.

Multi-center,randomized,and double-blind controlled clinical trial of duloxetine enteric capsule in treatment of depression

Plasma metabolomics and network pharmacology identified glutamate, glutamine, and arginine as biomarkers of depression under Shuganjieyu capsule treatment

Efficacy and Safety of Anjiaxin Capsules in Treatment of Mild or Moderate Depression

A Randomized, Double-Blind, Positive-Controlled, Multicenter Clinical Trial on the Efficacy and Safety of ShuganJieyu Capsule and St. John’s Wort for Major Depressive Disorder with Somatic Complaints

Tolerance of Bajitian oligosaccharide capsule in Chinese healthy volunteers